-
Posted by
Two Blokes Fri at 4:30 PM -
Filed in
Stock
-
2 views
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA.
